Good MorningA new trading year has begun, which should be good for investors. Easing monetary, regulatory, and tax headwinds are expected to accelerate economic activity and sustain upward momentum in stock prices.
The S&P 500 index ended 2024 on a downbeat, closing lower on the year's final day, but the uptrend is intact and expected to hit new highs early in the year. A move to new highs is also significant because of the technical signals, which indicate another 1,300-point gain by the end of the year.
This week and next week are critical for market direction in 2025. The labor data is due this week, and earnings from the big banks next. The labor data should align with trends, including steady job creation, low unemployment, and rising wages and earnings from the banks should be robust. Top financial firms, including banks like JPMorgan Chase, are expected to grow earnings by high-double digits, averaging nearly 40% for the group. Featured: AI Meltdown Imminent: Dump These Stocks Now! (Ad) 
|
Markets | | |
The concept of market relativity is more alive than ever in today’s economy, as gone are the days of individualistic price action in different asset classes and even stocks. With the advances in data delivery and technology, traders across the financial sector have found ways to connect the ... Read the Full Story |
|
From Our PartnersWhat If Washington Declared That:
YOUR Money ISN'T Actually Yours?
Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property.
What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want. | | | Get your free guide now by clicking here >> |
|
Markets | | |
Global enterprise software giant SAP SE (NYSE: SAP) has been scratching at all-time highs as its business gets lifted by artificial intelligence (AI) tailwinds. SAP is an acronym for Systems, Applications, and Products in Data Processing. The company provides cloud-based business softwar... Read the Full Story |
|
Markets | | | U.S. stock indexes slipped on Thursday as Wall Street’s weak end to last year carried into 2025. The S&P 500 fell 0.2% to extend the four-day losing streak that dimmed the close of its stellar 2024. The index pinballed through the day between an early gain of 0.9% and a later loss of 0.9% before... Read the Full Story |
|
From Our Partners2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines.
But even in uncertain times, innovation doesn’t slow down.
In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles.
Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar. | | | 👉[Click here to access your FREE AI stocks report now.] |
|
Markets | | | Stock indexes closed mostly lower Tuesday as the market delivered a downbeat finish on the final day of another milestone-shattering year on Wall Street.The S&P 500 gave up an early gain to finish down 0.4%. The benchmark index, which set 57 record highs in 2024, racked up a 23.3% gain for the y... Read the Full Story |
|
Stocks | | |
Artificial intelligence stocks are expected to continue showing strong growth in 2025. Much of the attention focuses on the opportunity that comes from the buildout of data centers. But a practical area where AI has been making significant inroads is healthcare.
For some investors, the fir... Read the Full Story |
|
|
Markets | | | U.S. stock markets will remain closed on Jan. 9 in honor of former President Jimmy Carter, continuing a long-held Wall Street tradition in mourning the nation’s leaders.Both the New York Stock Exchange and Nasdaq announced this week that they plan to close their equity and options markets next Thurs... Read the Full Story |
|
Markets | | |
The travel and leisure sectors are undergoing a transformation driven by the rising popularity of Bleisure travel—a blend of "business" and "leisure."
Bleisure travel represents a fundamental shift in how people approach travel. It reflects a broader societal trend where the boundaries... Read the Full Story |
|
Markets | | |
Tesla Inc (NASDAQ: TSLA) shares are rounding out a phenomenal year, delivering gains as much as 250% off the back of decent performance and a favorable macro environment. For example, much of this year’s rally has been fueled by strong investor sentiment following geopolitical developments... Read the Full Story |
|
Markets | | | China's factory activity expanded at a slower pace in December, official data showed on Tuesday, despite recent stimulus measures and in the face of increasing trade risks.The Purchasing Managers’ Index, based on a survey of factory managers, slipped to 50.1 in December from 50.3 the previous month,... Read the Full Story |
|
Markets | | | A New Jersey offshore wind project is seeking a second delay, saying it still can't find someone to build crucial equipment for the turbines in the latest patch of turbulence striking the industry.Leading Light Wind had already received one pause on its project from the New Jersey Board of Public Ut... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. | | View Today's Stock Pick |
|
